Corcept Therapeutics Inc’s recently made public that its Officer Robb Gary Charles acquired Company’s shares for reported $0.23 million on Jun 16 ’25. In the deal valued at $70.77 per share,3,185 shares were bought.
Then, Swisher Daniel N JR sold 2,200 shares, generating $155,342 in total proceeds. Upon selling the shares at $70.61, the Director now owns 0 shares.
Before that, Guyer William sold 20,000 shares. Corcept Therapeutics Inc shares valued at $1,448,475 were divested by the Chief Development Officer at a price of $72.42 per share. As a result of the transaction, Guyer William now holds 5,487 shares, worth roughly $0.39 million.
Truist upgraded its Corcept Therapeutics Inc [CORT] rating to a Buy from a a Hold in a research note published on November 06, 2023; the price target was increased to $38 from $29. A number of analysts have revised their coverage, including SVB Securities’s analysts, who began to cover the stock in mid April with a ‘”a Market perform”‘ rating. Piper Sandler began covering CORT with “an Overweight” recommendation on April 04, 2023. Jefferies revised its rating on February 15, 2023. It rated CORT as “a Hold” which previously was an “a Buy”.
Price Performance Review of CORT
On Monday, Corcept Therapeutics Inc [NASDAQ:CORT] saw its stock jump 1.20% to $70.90. Over the last five days, the stock has gained 0.47%. Corcept Therapeutics Inc shares have risen nearly 40.70% since the year began. Nevertheless, the stocks have risen 117.22% over the past one year. While a 52-week high of $117.33 was reached on 03/31/25, a 52-week low of $28.04 was recorded on 01/13/25.
Levels Of Support And Resistance For CORT Stock
The 24-hour chart illustrates a support level at 70.19, which if violated will result in even more drops to 69.48. On the upside, there is a resistance level at 71.34. A further resistance level may holdings at 71.78.
